Jason M. Glover

TL;DR: Analyses of samples from patients with acute myeloid leukaemia reveal that drug response is associated with mutational status and gene expression; the generated dataset provides a basis for future clinical and functional studies of this disease.

TL;DR: An algorithm to predict kinase pathway dependence based on analysis of inhibitor sensitivity patterns was developed and it was suggested that drug target scores derived from a comprehensive kinase inhibitor panel could predict pathway dependence in cancer cells while simultaneously identifying potential therapeutic options.

TL;DR: RNAi technology is used to identify a novel oncogenic pathway that involves aberrant activation of the TYK2 tyrosine kinase and its downstream substrate, STAT1, which ultimately promotes T-ALL cell survival through the upregulation of BCL2 expression.

TL;DR: The case of a patient with t(17;19)(q22;p13) gene rearranged B‐cell precursor ALL whose lymphoblasts were found to have significant in vitro sensitivity to dasatinib, whose patient tolerated the addition of dAsatinib with combination therapy and remained in remission for over nine months until his recurrence.

TL;DR: Results suggest that an adaptive Src-Pdgfra-Raf-Mapk axis is relevant to PDGFRA inhibition in rhabdomyosarcoma.